3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

[News]

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

More... (http://www.news-medical.net/news/20140917/3SBio-signs-exclusive-license-agreement-with-JenKem-for-PEG-irinotecan.aspx)